Skip to main content

Table 1 Clinical characteristics of people with type 2 diabetes with or without a prescription of SGLT-2i

From: Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis

Characteristic

T2DM prescribed SGLT-2i

(N = 26,700)

T2DM not prescribed SGLT-2i

(N = 215,924)

Age (years)

59.8 ± 10.9

67.5 ± 13.9

Male

15,680 (58.7)

118,958 (55.1)

Ethnicity

 White

17,735 (66.4)

142,664 (66.1)

 Asian

3369 (12.6)

23,559 (10.9)

 Black

804 (3.0)

8924 (4.1)

 Mixed

210 (0.8)

1752 (0.8)

 Other

279 (1.0)

2090 (1.0)

 Missing

4303 (16.1)

36,935 (17.1)

IMD quintile

 IMD quintile 5 (least deprived)

4984 (18.7)

44,284 (20.5)

 IMD quintile 4

5249 (19.7)

44,301 (20.5)

 IMD quintile 3

5063 (19.0)

41,355 (19.2)

 IMD quintile 2

4873 (18.3)

38,448 (17.8)

 IMD quintile 1 (most deprived)

5774 (21.6)

41,227 (19.1)

 Missing

757 (2.8)

6309 (2.9)

Duration of diabetes (years)

9.4 ± 6.3

9.3 ± 7.3

 < 1

1582 (5.9)

16,019 (7.4)

 1–4

5686 (21.3)

56,009 (25.9)

 5–9

8187 (30.7)

58,595 (27.1)

  ≥ 10

11,245 (42.1)

85,301 (39.5)

  1. Data are presented as n (%) or mean (± SD)
  2. IMD Index of Multiple Deprivation, SGLT-2i sodium–glucose co‐transporter‐2 inhibitor, T2DM Type 2 diabetes